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Abstract Cytochrome P450 (CYP) activity is very low or even
absent in human hepatomas, a phenomenon that is accompanied
by low levels of some liver transcription factors, notably C/
EBPK. To investigate a possible link between this transcription
factor and hepatic CYP expression, we have stably transfected
HepG2 cells with a C/EBPK vector containing a Zn-inducible
metallothionein promoter. Expression of functional C/EBPK up
to liver levels concomitantly increased the mRNAs of several
members of the CYP2 family (2B6, 2C9 and 2D6), suggesting
that this transcription factor may play a relevant role in
controlling the hepatic expression of CYP enzymes.
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1. Introduction
The cytochromes P450 (CYP) constitute a superfamily of
monooxygenases that participate in the metabolism of endog-
enous substrates and play a key role in the detoxi¢cation as
well as in the metabolic activation of xenobiotics [1,2]. Con-
stitutive liver CYP expression (and induction by exogenous/
endogenous compounds) appears to be regulated mainly at
the transcriptional level [3]. However, research into the precise
modulation mechanisms has been hampered by the fact that
CYP expression is almost absent in hepatoma cells and rap-
idly declines in primary cultured hepatocytes [4^6].
Studies on gene promoter and enhancer sequences have led
to the identi¢cation of several liver-speci¢c transcription fac-
tors that control the activation of many hepatic genes [7] and
may also possibly regulate CYP expression [8]. Human hep-
atoma HepG2 is a cell line that retains many hepatic biochem-
ical functions [9,10] with the notable exception of cytochrome
P450 [4]. Analysis of several hepatocyte-speci¢c transcription
factors (HNF-1, HNF-3, HNF-4, C/EBPK) in HepG2 re-
vealed that their levels were lower than in human hepatocytes,
especially in the case of C/EBPK. In order to investigate
whether this factor could play a role in the control of human
CYP transcription, we stably transfected HepG2 cells with a
C/EBPK expression vector containing a Zn-inducible metal-
lothionein promoter. Our results demonstrate that the expres-
sion of functional C/EBPK in HepG2 cells at levels like those
found in hepatocytes results in increased levels of CYP2B6,
CYP2C9 and CYP2D6 mRNAs, suggesting a probable role
for this transcription factor in the regulation of the constitu-
tive expression of genes of the CYP2 family.
2. Materials and methods
2.1. Cell culture and transfection
HepG2 cells were plated in Ham’s F-12/Leibovitz L-15 (1:1, v/v)
supplemented with 7% newborn calf serum, 50 U/ml penicillin, 50 mg/
ml streptomycin, and cultured to 70% con£uence. The plasmid
pPC22-C/EBPK (a kind gift of J. Patrick Condreay, Wellcome Re-
search Laboratories, NC) [11] is a 9.0-kb expression vector containing
a zinc-inducible, human metallothionein IIA promoter, driving ex-
pression of the rat C/EBPK gene (r-C/EBPK). This expression vector
was transfected into the human hepatoma HepG2 (ECACC 85011430)
using lipofectin (Gibco-BRL) according to the recommendations of
the manufacturer. Following transfection, cells were grown in medium
supplemented with 900 Wg/ml Geneticin (Gibco-BRL), and stable anti-
biotic-resistant clones were isolated. In parallel, control HepG2 were
transfected with the insertless vector. To induce maximal expression
of C/EBPK, 100 WM zinc-sulfate was added to the culture medium for
18^20 h.
2.2. Isolation and culture of human hepatocytes
Surgical liver biopsies (1^5 g) were obtained from patients under-
going cholecystectomy after informed consent was obtained. Patients
had no known liver pathology nor did they receive medication during
the weeks prior to surgery. None of the patients were habitual con-
sumers of alcohol or other drugs. A total of six liver biopsies (2 males
and 4 females) were used. Patients’ ages ranged from 26 to 71 years.
Human hepatocytes were isolated using a two-step perfusion tech-
nique [5] and seeded on plates coated with ¢bronectin (3.6 Wg/cm2)
at a density of 8U104 cells/cm2. Culture medium was Ham’s F-12/
Leibovitz L-15 (1:1, v/v) supplemented with 2% newborn calf serum,
5 mM glucose, 50 U/ml penicillin, 50 mg/ml streptomycin, 0.2%
bovine serum albumin and 1038 M insulin. The medium was changed
one hour later to remove unattached hepatocytes.
2.3. Extraction of nuclear proteins and Western blot analysis
HepG2 cells were lysed with Nonidet P-40 lysis bu¡er (10 mM Tris-
HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, and 0.5% Nonidet P-40).
The cell lysates were then incubated on ice for 15 min, and nuclei were
pelleted at 1000Ug for 5 min at 4‡C. The pellets were washed again
with lysis bu¡er, resuspended in 50 mM Tris-HCl (pH 7.4), 10 mM
magnesium acetate, 40% glycerol, and 1 mM dithiothreitol, and stored
at 370‡C until ready for use. Nuclear extracts were prepared as de-
scribed [12] and electrophoresed in an SDS-polyacrylamide gel (20 Wg
proteins/lane). Proteins were transferred to Immobilon membranes
(Millipore) and sheets were incubated with rabbit polyclonal antibody
raised against a peptide corresponding to amino acids 253^265 of rat
C/EBPK (Santa Cruz Biotechnology, Inc.). After washing, blots were
developed with horseradish peroxidase-labelled goat anti-rabbit IgG,
using an Enhanced Chemiluminescence Kit (Amersham Life Sciences).
2.4. Albumin synthesis in HepG2 cells
The synthesis and secretion of albumin were monitored by means of
an ELISA in samples of culture media taken at regular time intervals
[13].
2.5. Analysis of mRNA by semiquantitative RT-PCR
Total cellular RNA was extracted with RNeasy Total RNA Kits
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(Qiagen) and contaminating genomic DNA was removed by incuba-
tion with DNase I Ampli¢cation Grade (Gibco-BRL). RNA (1 Wg)
was reverse transcribed as described [14]. Diluted cDNA (3 Wl) was
ampli¢ed in 40 Wl of 20 mM Tris-HCl (pH 8.4) containing 50 mM
KCl, 1.5 mM MgCl2, 50 WM of each deoxynucleotide triphosphate,
1 U Taq DNA polymerase (Gibco-BRL) and 0.2 WM of each primer.
After denaturing for 4 min at 94‡C, ampli¢cation was performed by
27^35 cycles of 35 s at 94‡C, 45 s at 60‡C and 1 min at 72‡C, and a
¢nal extension of 5 min at 72‡C. Appropriate cDNA dilutions and
cycles were empirically determined for each mRNA to ensure that the
PCR-products would not reach the plateau of the ampli¢cation.
Under these conditions, the yield of the PCR is proportional to the
input cDNA [15]. For quantitative analysis, aliquots of the PCR re-
action (15 Wl) were mixed with diluted picogreen reagent (1:200 in TE
bu¡er) (Molecular Probes), stained samples were excited at 485 nm,
and the emission at 538 nm was read in a micro-plate spectro£uori-
meter [16]. Appropriate blank samples containing non-ampli¢ed
cDNA, primers, and PCR-mix were also included. Aliquots (25 Wl)
of the PCR reaction were subjected to electrophoresis on 1.5%
agarose gel, for size and purity con¢rmation. Sample-to-sample
variations were normalized by analysis of L-actin and/or GPDH
from the same cDNA dilution series.
2.6. Oligonucleotides
Oligonucleotides are mentioned in Table 1.
3. Results and discussion
3.1. CYP mRNA levels and expression of liver transcription
factors in the human hepatoma HepG2 and in cultured
human hepatocytes
The expression of CYP genes in HepG2 cells is very low
when compared with human hepatocytes (see as an example
CYP2C9, Fig. 1A). This phenomenon could be due to a tran-
scriptional block of CYP genes or to lack of expression of
appropriate transactivating factors in the tumor cell line.
Analysis of four major hepatocyte-speci¢c transcription fac-
tors (HNF-1, HNF-3, HNF-4, C/EBPK) in HepG2 cells
showed low levels of C/EBPK mRNA (ca. 15% of human
hepatocytes), followed by HNF-3 (25%) and HNF-1 (40%).
This contrasts with the measured HNF-4 mRNA which was
close to that found in 20-h cultured hepatocytes (Fig. 1A).
A decrease in the mRNA of the above mentioned transcrip-
tion factors is also observed during the isolation and culture
of hepatocytes, a phenomenon that is concomitant with the
decrease in CYP mRNAs. Of the various transcription factors
investigated, C/EBPK showed the earliest and fastest decay
during the initial stages of culture (Fig. 1B).
Recent results in our laboratory showed that culturing hep-
atocytes in collagen gels, a technique that greatly improves the
expression and inducibility of CYPs, resulted in the mainte-
nance of key transcription factors, notably C/EBPK, at the
levels found in freshly isolated hepatocytes [17]. This ¢nding
together with the data reported here led us to consider C/
EBPK a potential transcription factor regulating CYP expres-
sion in hepatocytes.
3.2. Stable transfection of HepG2 cells with C/EBPK
To test the previous hypothesis we stably transfected the
plasmid pPC22-C/EBPK into HepG2. It has been reported
that C/EBPK has a strong antiproliferative role [18,19]. Con-
sequently, high expression levels of this factor in transfected
cells could be incompatible with cell growth and make the
cloning stage more di⁄cult. To overcome this potential draw-
back a plasmid containing a zinc-inducible human metallo-
thionein IIA promoter was used [11]. This vector ensures
low basal expression of C/EBPK and cell growth in the ab-
sence of the cation, but promotes high expression of the trans-
gene when the culture medium is supplemented with Zn2.
Upon lipofectin transfection the antibiotic-resistant clones
were screened by Western blot analysis of nuclear extracted
proteins.
As shown in Fig. 2A, a strong antibody-stained p42-C/
EBPK protein was observed in transfected HepG2 cells upon
stimulation with 100 WM ZnSO4, but not in the nuclear ex-
tracts of cells transfected with an insertless vector. The level of
the expressed protein was similar to that found in freshly
isolated hepatocytes. A second protein band of ca. 30 kDa
was also recognized in nuclear extracts of hepatocytes, which
evidences the presence of the two translation products derived
from the endogenous C/EBPK mRNA (p42 and p30 proteins)
[20].
To verify that the expressed factor was functional, its e¡ects
on albumin, a well characterized target gene [21], were exam-
ined. Addition of Zn2 to culture media of C/EBPK-express-
ing cells resulted in a signi¢cant increase in albumin synthesis
(Fig. 2B), which reached values similar to those found in 24-h
cultured human hepatocytes (18.5 þ 2.56 ng albumin/min/mg).
These results proved that in transfected HepG2 clones re-ex-
pression of functional C/EBPK up to a level su⁄cient to trans-
activate an endogenous hepatic-speci¢c gene was possible.
3.3. Human CYP mRNA levels in C/EBPK-expressing cells
To determine whether C/EBPK plays a role in CYP expres-
sion in hepatic cells, we measured CYP mRNA levels in
HepG2 clones stably transfected with C/EBPK. The human
cytochrome P450 gene superfamily comprises more than 35
di¡erent isoenzymes grouped in 14 families [22]. In the present
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Table 1
Gene Accession 5P nt Forward primer 5P nt Reverse primer
CYP2B6 M29874 1256 atg ggg cac tga aaa aga ctg a 1538 aga ggc ggg gac act gaa tga c
CYP2C9 M61855 1285 ttc atg cct ttc tca gca gg 1668 ttg cac agt gaa aca tag ga
CYP2D6 X08006 1169 cta agg gaa cga cac tca tca c 1457 ctc acc agg aaa gca aag aca c
CYP2E1 J02625 913 aca gag acc acc agc aca act 1492 atg agc ggg gaa tga cac aga
CYP3A4 M14096 1353 cct tac aca tac aca ccc ttt gga agt 1734 agc tca atg cat gta cag aat ccc cgg tta
CYP3A5 J04813 855 gaa gaa aag tcg cct caa c 1533 aag aag tcc ttg cgt gtc ta
C/EBPK U34070 1513 gtg gag acg cag cag aag 1962 ttc caa ggc aca agg tta tc
HNF-1(K) M57732 1223 cca gaa cct cat cat ggc ctc act 1550 cac ctc ggg ctt gtg gct gta gag
HNF-3K U39840 1571 cag caa aca aaa cca cac aaa 1859 taa ata acc ctc cac aaa cta
HNF-4 X87871 916 gcc tac ctc aaa gcc atc at 1190 gac cct ccc agc agc atc tc
G6PDH X03674 1293 aag ccc gcc tcc acc aac tca 1528 ggc acc cca tcc cac ctc tca t
L-Actin X00351 480 cgt acc act ggc atc gtg at 931 gtg ttg gcg tac agg tct ttg
r-C/EBPK X12752 679 ccc gtg ccc agc cct cat 942 cac ctt ctg ctg cgt ctc cac
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study we focused on six P450 isoenzymes belonging to the
CYP2 and CYP3 families, which encompass the most relevant
xenobiotic-metabolizing P450s in man [23]. Upon activating
the expression of C/EBPK with Zn2, the mRNA levels of
CYP2B6, 2C9 and 2D6 clearly increased (ca. 5.5-, 12.8- and
2.2-fold, respectively, relative to the ‘housekeeping’ GPDH
mRNA; averaged results from 3^4 independent experiments).
We did not observe signi¢cant changes in the levels of
CYP2E1 and 3A4/5 mRNA (Fig. 3).
The increased expression of these CYP genes upon expres-
sion of ectopic C/EBPK mRNA indicates that this transcrip-
tion factor must play a relevant role. The experimental evi-
dence reported in our paper certainly does not prove the
direct e¡ect of C/EBPK on the promoter and enhancer se-
quences of these CYP genes, but some indirect evidence points
to the feasibility of a direct transactivation mechanism. Com-
puter sequence analysis of the 5P-£anking regions of the hu-
man CYP2C9 and CYP2D6 genes (the CYP2B6 gene has not
been cloned yet) has revealed several consensus binding sites
for C/EBP proteins [24,25]. In addition, transient transfection
experiments have shown that C/EBPK could have a direct
activating e¡ect on rat CYP2B [26] and CYP2C [27] pro-
moters, but not on the rat CYP2E1 promoter [28]. Finally,
the mRNA levels of human HNF-1, HNF-3 and HNF-4 were
not altered in the C/EBPK expressing clones (data not shown).
This rules out the possibility of cross-activation among C/
EBPK and the above mentioned liver-enriched transcription
factors, which could indirectly a¡ect CYP gene transcription.
Rather, it suggests that C/EBPK is probably the regulator that
transactivates CYP2B6, CYP2C9 and CYP2D6 genes. This
study also shows for the ¢rst time that a simultaneous re-
activation of several CYP genes can be elicited by re-express-
ing a missing transcription factor in human hepatoma cells.
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Fig. 1. Liver transcription factors and CYP2C9 mRNA in the hu-
man hepatoma HepG2 (A) and in human hepatocytes (B). Total
RNA was puri¢ed from HepG2 cells, liver biopsy, isolated (0 h)
and cultured hepatocytes (3^6 h), and speci¢c mRNA levels were
measured by semi-quantitative RT-PCR. Sample-to-sample varia-
tions were normalized by comparative analysis of L-actin. Bars rep-
resent mean þ S.D. (n = 3) (A), and symbols represent averaged re-
sults from 3^4 independent experiments (B).
Fig. 2. Stable transfection of functional C/EBPK in HepG2. Hepato-
ma cells were transfected with the plasmid pPC22-C/EBPK (HepG2-
C/EBPK) or the insertless vector (HepG2-Control). G418-resistant
clones were exposed (+) or not (3) to 100 WM ZnSO4 for 18 h. A:
Western blot analysis of nuclear extracts (20 Wg) from representative
clones (lanes 1^4) and freshly isolated hepatocytes (lane 5) stained
with rabbit anti-C/EBPK antibody. B: ELISA quanti¢cation of al-
bumin synthesis in control and C/EBPK expressing cells. Bars repre-
sent mean þ S.D. (n = 4).
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Fig. 3. RT-PCR analysis of CYP mRNAs in C/EBPK expressing cells. cDNAs from transfected HepG2 cells incubated with 100 WM ZnSO4
for 18 h were serially diluted and ampli¢ed with speci¢c primers. After gel electrophoresis of the PCR products and staining with ethidium bro-
mide, the £uorescent bands were recorded with a video camera. M: 100-bp DNA ladder.
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